Akari Therapeutics, Plc
AKTX
$1.07
-$0.04-3.60%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 4.77% | 5.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -17.11% | -22.73% |
| Operating Income | -- | -- | -- | 17.11% | 22.73% |
| Income Before Tax | -- | -- | -- | 50.48% | 53.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | 50.48% | 53.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 50.48% | 53.63% |
| EBIT | -- | -- | -- | 17.11% | 22.73% |
| EBITDA | -- | -- | -- | 17.11% | 22.74% |
| EPS Basic | -- | -- | -- | 70.06% | 71.19% |
| Normalized Basic EPS | -- | -- | -- | 70.06% | 71.19% |
| EPS Diluted | -- | -- | -- | 70.02% | 71.14% |
| Normalized Diluted EPS | -- | -- | -- | 70.02% | 71.14% |
| Average Basic Shares Outstanding | -- | -- | -- | 53.82% | 50.87% |
| Average Diluted Shares Outstanding | -- | -- | -- | 56.36% | 54.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
